Skip to content
Screener

Veracyte VCYT Biopharmaceutical and other revenue — Other cost

Other product segments

Testing revenue
$4.94M+45.8%

Similar metrics at other companies

Chatham Lodging Trust logo
CLDTHotel — Other Cost Of Operating Revenue
$1.12M+8.8%
Target Hospitality logo
THAll Other Segments — Other Cost Of Operating Revenue
$36K+9.1%
Halliburton logo
HALCompletion And Production — Other Cost of Operating Revenue
$723M+3.0%
Halliburton logo
HALDrilling And Evaluation — Other Cost of Operating Revenue
$515M+2.6%
Target Hospitality logo
THGovernment — Other Cost Of Operating Revenue
$63K-30.0%
Archer Aviation logo
ACHRReportable Segment — Other cost of revenue
$900K—

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$3.71B+97.6%
Enterprise value$3.48B+104%
P/E42.2×-29.1×
P/S6.9×+2.9×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0×0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:OtherCostOfOperatingRevenue.

The source filing: Veracyte’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 8:07 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001384101-26-000031
Line itemThree Months Ended March 31, 20262025
Total cost of product revenue1,8911,422
Cost of biopharmaceutical and other revenue:
Compensation expense—1,240
Other cost of biopharmaceutical and other revenue (3)81,044
Allocation of facilities and IT expenses—414
Total cost of biopharmaceutical and other revenue82,698
Intangible asset amortization - cost of revenue2,7072,585
Gross profit101,15979,508

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Veracyte's biopharmaceutical and other revenue — other cost?
Veracyte (VCYT) reported biopharmaceutical and other revenue — other cost of $8K in Q1 2026.
How has Veracyte's biopharmaceutical and other revenue — other cost changed year-over-year?
Veracyte's biopharmaceutical and other revenue — other cost decreased by 99.2% year-over-year, from $1.04M to $8K.
What is the long-term trend for Veracyte's biopharmaceutical and other revenue — other cost?
Over 3 years (2022 to 2025), Veracyte's biopharmaceutical and other revenue — other cost has grown at a -29.0% compound annual growth rate (CAGR), from $9.3M to $3.33M.
What does biopharmaceutical and other revenue — other cost mean?
This metric encompasses miscellaneous operational expenses directly tied to the biopharmaceutical segment that are not classified as direct labor or facility allocations. It is used to monitor the variable overhead and incidental costs associated with maintaining research partnerships.

Ask your AI about Veracyte's biopharmaceutical and other revenue — other cost.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude